Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Effect of Supplementation With Vitamins D3 and K2 in Non-carboxyled Osteocalcine and Insulin Serum Levels in Patients With Diabetes Mellitus Type 2
Introduction: Patients with DM2 have chronic hyperglycemia derived from a decrease in insulin
sensitivity, cause of comorbidities such as bone demineralization, decreasing quality of life
and increasing mortality. This could be related to changes in the serum levels of
carboxylated Osteocalcin and Insulin, together with the deficit the daily consumption of
vitamins D3 and K, which is crucial for the process of mineralization of the bone matrix.
Research question: What is the effect of supplementation with Vitamins D3 and K2 on serum
levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus?
Hypothesis: Supplementation with Vitamins D3 and K2 modifies the serum levels of Carboxylated
Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus.
General Objectives: To assess the effect of supplementation with Vitamins D3 and K2 on serum
levels of Carboxylated and Non-Carboxylated Osteocalcin in patients with Type 2 Diabetes
mellitus.
Material and Methods: Clinical trial, double blind, randomization, 40 patients with DM2,
35-65 years, supplementation (3 months), clinical and laboratory determinations (uOC and
Insulin).
- Group 1: Vitamin D3 1000UI + Placebo
- Group 2: Vitamin K2 100 mcg + Placebo
- Group 3 (Positive Control): Vitamins D3 1000UI + K2 100 mcg
Type 2 diabetes mellitus is a group of metabolic disorders characterized by chronic
hyperglycemia, being one of the main causes of mortality in our country.
There are different comorbidities, including bone demineralization, which involve an
imbalance in the process of bone formation and resorption, which entails the risk of
decreasing bone mineral density. These processes could be related to the serum levels of
Non-carboxylated Osteocalcin and Insulin, said molecule locally modulates the process of bone
mineralization.
On the other hand, it is known that the daily consumption of vitamins in a general diet in
our population (specifically including vitamins D3 and K), is below the necessary basic
requirements, so considering crucial elements for the benefit of Bone matrix mineralization,
which is why the present study proposes supplementation with the aforementioned vitamins in
patients with Type 2 DM, to avoid a decrease in bone mineral density, increasing the
mortality rate of individuals suffering from it.
1. - The study subjects from the West of the country were invited to participate in the
research protocol, where their objective was explained and the signing of the consent
was requested under information, where a structured evaluation was subsequently carried
out consisting of :
a) Comprehensive clinical evaluation (including general sociodemographic data of a
complete medical history).
2. - Once the previous data was obtained, the randomization of the treatment was carried
out, classifying the patients in the following groups:
- Group 1 Vitamin D3 1000UI + Placebo (Calcined Magnesia).
- Group 2 Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
- Group 3 (Positive Control) Vitamins D3 1000UI + K2 100 mcg.
3. - Blood sample collection through Punzocat, which was placed in a red tube, for
subsequent centrifugation at 3500rpm x 15 minutes, performing aliquots of the serum
obtained and stored at -80 ° C and thus perform the pertinent quantifications of the
molecules to study.
4. - Quantification of serum levels of non-carboxylated Osteocalcin and Insulin
a) The determinations corresponding to the serum levels of Non-carboxylated Osteocalcin
and Insulin were made, both baseline prior to the intervention as well as the final
quantification, once the supplementation was finished, by means of the indirect ELISA
technique (commercial reagents -Takara were used - for the realization of these
determinations), which involved the following process: In a plate the wells were coated
with a first antibody, then a wash was performed to remove the excess antibody, after
that, the sample in which the antigen was found was added, which was retained in the
well after being recognized by the first antibody, a second wash was subsequently made
to remove unbound material, then a solution with a second labeled anti-antigen antibody
was applied. Thus each antigen molecule was bound to an antibody in the base that kept
it fixed and a second antibody for its reaction and labeling. Finally, the plate was
introduced into a spectophotometer and the absorbance was measured at a length of 450
nm, for both non-carboxylated Osteocalcin and Insulin.
5. - The quantification in serum of cholesterol and triglycerides was carried out by using
the fully automated random access analyzer equipment for clinical chemistry, model ERBA
XL 200.
6. - The evaluation of the HOMA index was calculated by using the equations HOMA-IR and
HOMA-B, for insulin resistance (IR) and Percentage, respectively.
7. - The daily of adherence to treatment was provided, so that they recorded all those
important events that would ensure adequate intake of vitamins, as well as adverse
reactions to them, which were evaluated in scheduled appointments, in addition to each
The corresponding bottles were delivered consecutively for each of the 3 months of
intervention, with the corresponding vitamins for each patient according to their
allocation group.
8. - Finally, in the last visit the results obtained during the whole study were made known
to each of the patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |